Frontiers in Medicine (Mar 2023)

Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome

  • Simon Bossart,
  • S. Morteza Seyed Jafari,
  • Kristine Heidemeyer,
  • Kexiang Yan,
  • Laurence Feldmeyer,
  • Luca Borradori,
  • Nikhil Yawalkar

DOI
https://doi.org/10.3389/fmed.2023.1050230
Journal volume & issue
Vol. 10

Abstract

Read online

Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.

Keywords